CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2025 and Provides Business Updates

Group 1 - The German Federal Cartel Office has cleared the planned transaction between BioNTech and CureVac, which is a significant step towards the expected closing later this year [1] - The offer period for BioNTech's public exchange offer for all outstanding CureVac N.V. shares began on October 21, 2025, and is set to expire on December 3, 2025 [1] - Ongoing German litigation involving Pfizer/BioNTech related to mRNA-based COVID-19 vaccines has been paused pending the completion of BioNTech's public exchange offer [1] Group 2 - CureVac has received Clinical Trial Application (CTA) clearance from the European Medicines Agency (EMA) for its CVHNLC squamous non-small cell lung cancer (sqNSCLC) [1] - The Phase 1 Part B trial for CVGBM (glioblastoma) remains on track [1] - As of September 30, 2025, CureVac reported a strong cash and cash equivalents position of €416.1 million, confirming an expected cash runway into 2028 [1] Group 3 - CureVac received the final audit report related to the Advance Purchase Agreement with the European Commission for its first-generation COVID-19 vaccine candidate [1]